Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.
Market Cap:165.5M; Shares Outstanding:40.6M; Short Interest: 1.97%; Q3 2019(9/30/19): Cash 72.79M. Loss 10.17M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 63，no change
Shares hold: 11238.7k shares. no change
shares% hold: 27.71%，no change